Active Biotech AB's Project ANYARA Improved Overall Survival in a Subgroup of Renal Cell Cancer Patients
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented overall survival (OS) and Progression Free Survival (PFS) data from the ANYARA Phase II/III study in renal cell cancer at the scientific conference "2013 ASCO Annual Meeting" held in Chicago (USA).
Help employers find you! Check out all the jobs and post your resume.
Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented overall survival (OS) and Progression Free Survival (PFS) data from the ANYARA Phase II/III study in renal cell cancer at the scientific conference "2013 ASCO Annual Meeting" held in Chicago (USA).
Help employers find you! Check out all the jobs and post your resume.